{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:49:59Z","timestamp":1787237399813,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,10]]},"DOI":"10.7759\/cureus.66555","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T03:45:46Z","timestamp":1723261546000},"source":"Crossref","is-referenced-by-count":7,"title":["Antiphospholipid Syndrome and Catastrophic Antiphospholipid Syndrome: A Comprehensive Review of Pathogenesis, Clinical Features, and Management Strategies"],"prefix":"10.7759","author":[{"given":"Avinash","family":"Parepalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Sarode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manikanta","family":"Nelakuditi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Jayanth","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Antiphospholipid Syndrome","author":"Bustamante JG","year":"2024","unstructured":"Bustamante JG, Goyal A, Rout P, Singhal M. Antiphospholipid Syndrome. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref2","unstructured":"Antiphospholipid syndrome and pregnancy. background, pathophysiology, etiology. (2024). Accessed: April 26, 2024: https:\/\/emedicine.medscape.com\/article\/261691-overview."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010668","article-title":"Catastrophic antiphospholipid syndrome","volume":"25","author":"Bitsadze V","year":"2024","unstructured":"Bitsadze V, Yakubova F, Khizroeva J, et al.. Catastrophic antiphospholipid syndrome. Int J Mol Sci. 2024, 25:668. 10.3390\/ijms25010668","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead571","article-title":"Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations","volume":"63","author":"Gaspar P","year":"2024","unstructured":"Gaspar P, Sciascia S, Tektonidou MG. Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations. Rheumatology (Oxford). 2024, 63:SI24-36. 10.1093\/rheumatology\/kead571","journal-title":"Rheumatology (Oxford)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00085","article-title":"The multidisciplinary team (MDT) approach and quality of care","volume":"10","author":"Taberna M","year":"2020","unstructured":"Taberna M, Gil Moncayo F, Jan\u00e9-Salas E, et al.. The multidisciplinary team (MDT) approach and quality of care. Front Oncol. 2020, 10:85. 10.3389\/fonc.2020.00085","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00764","article-title":"New biomarkers for atherothrombosis in antiphospholipid syndrome: genomics and epigenetics approaches","volume":"10","author":"Lopez-Pedrera C","year":"2019","unstructured":"Lopez-Pedrera C, Barbarroja N, Pati\u00f1o-Trives AM, Collantes E, Aguirre MA, Perez-Sanchez C. New biomarkers for atherothrombosis in antiphospholipid syndrome: genomics and epigenetics approaches. Front Immunol. 2019, 10:764. 10.3389\/fimmu.2019.00764","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317731532","article-title":"Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis","volume":"27","author":"Abdel-Wahab N","year":"2018","unstructured":"Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus. 2018, 27:572-83. 10.1177\/0961203317731532","journal-title":"Lupus"},{"key":"ref8","article-title":"Drug-Induced Lupus Erythematosus","author":"Solhjoo M","year":"2024","unstructured":"Solhjoo M, Goyal A, Chauhan K. Drug-Induced Lupus Erythematosus. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308090025","article-title":"Pathogenic role of antiphospholipid antibodies","volume":"17","author":"Salmon JE","year":"2008","unstructured":"Salmon JE, de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus. 2008, 17:405-11. 10.1177\/0961203308090025","journal-title":"Lupus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi S","year":"2021","unstructured":"Chaturvedi S, Braunstein EM, Brodsky RA. Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications. J Thromb Haemost. 2021, 19:607-16. 10.1111\/jth.15082","journal-title":"J Thromb Haemost"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01840","article-title":"Mechanisms of endothelial dysfunction in antiphospholipid syndrome: association with clinical manifestations","volume":"9","author":"Vel\u00e1squez M","year":"2018","unstructured":"Vel\u00e1squez M, Rojas M, Abrahams VM, Escudero C, Cadavid \u00c1P. Mechanisms of endothelial dysfunction in antiphospholipid syndrome: association with clinical manifestations. Front Physiol. 2018, 9:1840. 10.3389\/fphys.2018.01840","journal-title":"Front Physiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030741","article-title":"Platelets and thrombotic antiphospholipid syndrome","volume":"13","author":"Tohidi-Esfahani I","year":"2024","unstructured":"Tohidi-Esfahani I, Mittal P, Isenberg D, Cohen H, Efthymiou M. Platelets and thrombotic antiphospholipid syndrome. J Clin Med. 2024, 13:741. 10.3390\/jcm13030741","journal-title":"J Clin Med"},{"key":"ref13","article-title":"Deep Vein Thrombosis","author":"Waheed SM","year":"2024","unstructured":"Waheed SM, Kudaravalli P, Hotwagner DT. Deep Vein Thrombosis. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/2048872612441582","article-title":"Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease","volume":"1","author":"Badimon L","year":"2012","unstructured":"Badimon L, Padr\u00f3 T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care. 2012, 1:60-74. 10.1177\/2048872612441582","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00536-9","article-title":"Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19","volume":"21","author":"Bonaventura A","year":"2021","unstructured":"Bonaventura A, Vecchi\u00e9 A, Dagna L, et al.. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021, 21:319-29. 10.1038\/s41577-021-00536-9","journal-title":"Nat Rev Immunol"},{"key":"ref16","article-title":"Antiphospholipid syndrome","author":"Garc\u00eda-Carrasco M","year":"2013","unstructured":"Garc\u00eda-Carrasco M, Mendoza Pinto C, Jim\u00e9nez Hern\u00e1ndez C, et al.. Antiphospholipid syndrome. Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al. (ed): El Rosario University Press, Bogota, Colombia; 2013."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932181","article-title":"Relationship between gender differences and clinical outcome in patients with the antiphospholipid syndrome","volume":"13","author":"Truglia S","year":"2022","unstructured":"Truglia S, Capozzi A, Mancuso S, et al.. Relationship between gender differences and clinical outcome in patients with the antiphospholipid syndrome. Front Immunol. 2022, 13:932181. 10.3389\/fimmu.2022.932181","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-009-8192-4","article-title":"The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies","volume":"40","author":"Weckerle CE","year":"2011","unstructured":"Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol. 2011, 40:42-9. 10.1007\/s12016-009-8192-4","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01124-z","article-title":"Neurologic manifestations of the antiphospholipid syndrome \u2014 an update","volume":"21","author":"Leal Rato M","year":"2021","unstructured":"Leal Rato M, Bandeira M, Rom\u00e3o VC, Aguiar de Sousa D. Neurologic manifestations of the antiphospholipid syndrome \u2014 an update. Curr Neurol Neurosci Rep. 2021, 21:41. 10.1007\/s11910-021-01124-z","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref20","article-title":"Antiphospholipid syndrome during pregnancy: the state of the art","volume":"5","author":"Di Prima FA","year":"2011","unstructured":"Di Prima FA, Valenti O, Hyseni E, et al.. Antiphospholipid syndrome during pregnancy: the state of the art. J Prenat Med. 2011, 5:41-53.","journal-title":"J Prenat Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094956","article-title":"How we interpret thrombosis with thrombocytopenia syndrome?","volume":"25","author":"Yamada S","year":"2024","unstructured":"Yamada S, Asakura H. How we interpret thrombosis with thrombocytopenia syndrome?. Int J Mol Sci. 2024, 25:4956. 10.3390\/ijms25094956","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082164","article-title":"Laboratory diagnosis of antiphospholipid syndrome: insights and hindrances","volume":"11","author":"Vandevelde A","year":"2022","unstructured":"Vandevelde A, Devreese KM. Laboratory diagnosis of antiphospholipid syndrome: insights and hindrances. J Clin Med. 2022, 11:2164. 10.3390\/jcm11082164","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.07.006","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"31","author":"Chaturvedi S","year":"2017","unstructured":"Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017, 31:406-17. 10.1016\/j.blre.2017.07.006","journal-title":"Blood Rev"},{"key":"ref24","article-title":"Antiphospholipid Antibody Testing","author":"Arcilla CK","year":"2024","unstructured":"Arcilla CK, Zubair M. Antiphospholipid Antibody Testing. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.707","article-title":"Prevention of thrombosis in antiphospholipid syndrome","volume":"2016","author":"Lim W","year":"2016","unstructured":"Lim W. Prevention of thrombosis in antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2016, 2016:707-13. 10.1182\/asheducation-2016.1.707","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030675","article-title":"Pathogenesis, diagnosis and management of obstetric antiphospholipid syndrome: a comprehensive review","volume":"11","author":"Alijotas-Reig J","year":"2022","unstructured":"Alijotas-Reig J, Esteve-Valverde E, Anunciaci\u00f3n-Llunell A, Marques-Soares J, Pardos-Gea J, Mir\u00f3-Mur F. Pathogenesis, diagnosis and management of obstetric antiphospholipid syndrome: a comprehensive review. J Clin Med. 2022, 11:675. 10.3390\/jcm11030675","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.9717.1","article-title":"Recent advances in understanding antiphospholipid syndrome","volume":"5","author":"Bertolaccini ML","year":"2016","unstructured":"Bertolaccini ML, Sanna G. Recent advances in understanding antiphospholipid syndrome. F1000Res. 2016, 5:2908. 10.12688\/f1000research.9717.1","journal-title":"F1000Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/immuno4010001","article-title":"Catastrophic antiphospholipid syndrome: a review","volume":"4","author":"Siniscalchi C","year":"2024","unstructured":"Siniscalchi C, Basaglia M, Riva M, Meschi M, Meschi T, Castaldo G, Di Micco P. Catastrophic antiphospholipid syndrome: a review. Immuno. 2024, 4:1-13. 10.3390\/immuno4010001","journal-title":"Immuno"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2012.44.1.63","article-title":"Five cases report of solid tumor synchronously with hematologic malignancy","volume":"44","author":"Cui Y","year":"2012","unstructured":"Cui Y, Liu T, Zhou Y, Ji Y, Hou Y, Jin W, Feng Y. Five cases report of solid tumor synchronously with hematologic malignancy. Cancer Res Treat. 2012, 44:63-8. 10.4143\/crt.2012.44.1.63","journal-title":"Cancer Res Treat"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13113064","article-title":"Management of cardiovascular complications in antiphospholipid syndrome: a narrative review with a focus on older adults","volume":"13","author":"Bernardi M","year":"2024","unstructured":"Bernardi M, Spadafora L, Andaloro S, et al.. Management of cardiovascular complications in antiphospholipid syndrome: a narrative review with a focus on older adults. J Clin Med. 2024, 13:3064. 10.3390\/jcm13113064","journal-title":"J Clin Med"},{"key":"ref31","article-title":"Physiology, Von Willebrand Factor","author":"Cortes GA","year":"2024","unstructured":"Cortes GA, Moore MJ, El-Nakeep S. Physiology, Von Willebrand Factor. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X13502919","article-title":"Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease","volume":"5","author":"Aguiar CL","year":"2013","unstructured":"Aguiar CL, Erkan D. Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther Adv Musculoskelet Dis. 2013, 5:305-14. 10.1177\/1759720X13502919","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref33","article-title":"Acute Respiratory Dstress Syndrome","author":"Diamond M","year":"2024","unstructured":"Diamond M, Peniston HL, Sanghavi DK, Mahapatra S. Acute Respiratory Dstress Syndrome. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref34","article-title":"Renal Vein Thrombosis","author":"Mazhar HR","year":"2024","unstructured":"Mazhar HR, Aeddula NR. Renal Vein Thrombosis. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.12860\/jnp.2014.03","article-title":"Catastrophic antiphospholipid syndrome: a clinical review","volume":"3","author":"Nayer A","year":"2014","unstructured":"Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol. 2014, 3:9-17. 10.12860\/jnp.2014.03","journal-title":"J Nephropathol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030735","article-title":"Clinical management of thrombotic antiphospholipid syndrome","volume":"11","author":"Tumian NR","year":"2022","unstructured":"Tumian NR, Hunt BJ. Clinical management of thrombotic antiphospholipid syndrome. J Clin Med. 2022, 11:735. 10.3390\/jcm11030735","journal-title":"J Clin Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1037\/amp0000517","article-title":"Lifestyle modification approaches for the treatment of obesity in adults","volume":"75","author":"Wadden TA","year":"2020","unstructured":"Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020, 75:235-51. 10.1037\/amp0000517","journal-title":"Am Psychol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11236984","article-title":"Anticoagulant therapy in patients with antiphospholipid syndrome","volume":"11","author":"Capecchi M","year":"2022","unstructured":"Capecchi M, Abbattista M, Ciavarella A, Uhr M, Novembrino C, Martinelli I. Anticoagulant therapy in patients with antiphospholipid syndrome. J Clin Med. 2022, 11:6984. 10.3390\/jcm11236984","journal-title":"J Clin Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e24","article-title":"Management of women with antiphospholipid antibodies or antiphospholipid syndrome during pregnancy","volume":"36","author":"Lee EE","year":"2021","unstructured":"Lee EE, Jun JK, Lee EB. Management of women with antiphospholipid antibodies or antiphospholipid syndrome during pregnancy. J Korean Med Sci. 2021, 36:e24. 10.3346\/jkms.2021.36.e24","journal-title":"J Korean Med Sci"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021331","article-title":"Hydroxychloroquine as an immunomodulatory and antithrombotic treatment in antiphospholipid syndrome","volume":"24","author":"Arachchillage DJ","year":"2023","unstructured":"Arachchillage DJ, Laffan M, Pericleous C. Hydroxychloroquine as an immunomodulatory and antithrombotic treatment in antiphospholipid syndrome. Int J Mol Sci. 2023, 24:1331. 10.3390\/ijms24021331","journal-title":"Int J Mol Sci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000269","article-title":"Treatment of catastrophic antiphospholipid syndrome","volume":"28","author":"Kazzaz NM","year":"2016","unstructured":"Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol. 2016, 28:218-27. 10.1097\/BOR.0000000000000269","journal-title":"Curr Opin Rheumatol"},{"key":"ref42","article-title":"Anticoagulation","author":"Umerah C o","year":"2024","unstructured":"Umerah C o, Momodu II. Anticoagulation. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.813358","article-title":"Role of dexamethasone and methylprednisolone corticosteroids in coronavirus disease 2019 hospitalized patients: a review","volume":"13","author":"Mehta J","year":"2022","unstructured":"Mehta J, Rolta R, Mehta BB, Kaushik N, Choi EH, Kaushik NK. Role of dexamethasone and methylprednisolone corticosteroids in coronavirus disease 2019 hospitalized patients: a review. Front Microbiol. 2022, 13:813358. 10.3389\/fmicb.2022.813358","journal-title":"Front Microbiol"},{"key":"ref44","article-title":"Systemic Lupus Erythematosus","author":"Justiz Vaillant AA","year":"2024","unstructured":"Justiz Vaillant AA, Goyal A, Varacallo M. Systemic Lupus Erythematosus. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145145","article-title":"An update on the biologics for the treatment of antiphospholipid syndrome","volume":"14","author":"Yun Z","year":"2023","unstructured":"Yun Z, Duan L, Liu X, Cai Q, Li C. An update on the biologics for the treatment of antiphospholipid syndrome. Front Immunol. 2023, 14:1145145. 10.3389\/fimmu.2023.1145145","journal-title":"Front Immunol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.521","article-title":"The effect of multidisciplinary care teams on intensive care unit mortality","volume":"170","author":"Kim MM","year":"2010","unstructured":"Kim MM, Barnato AE, Angus DC, Fleisher LA, Kahn JM. The effect of multidisciplinary care teams on intensive care unit mortality. Arch Intern Med. 2010, 170:369-76. 10.1001\/archinternmed.2009.521","journal-title":"Arch Intern Med"},{"key":"ref47","article-title":"Continuous Renal Replacement Therapy","author":"Saunders H","year":"2024","unstructured":"Saunders H, Rehan A, Hashmi MF, Sanghavi DK. Continuous Renal Replacement Therapy. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-023-02834-6","article-title":"Positive antiphospholipid antibodies: observation or treatment?","volume":"56","author":"Grygiel-G\u00f3rniak B","year":"2023","unstructured":"Grygiel-G\u00f3rniak B, Mazurkiewicz \u0141. Positive antiphospholipid antibodies: observation or treatment?. J Thromb Thrombolysis. 2023, 56:301-14. 10.1007\/s11239-023-02834-6","journal-title":"J Thromb Thrombolysis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015733","article-title":"Pregnancy outcomes in patients with primary antiphospholipid syndrome: a systematic review and meta-analysis","volume":"98","author":"Liu L","year":"2019","unstructured":"Liu L, Sun D. Pregnancy outcomes in patients with primary antiphospholipid syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2019, 98:e15733. 10.1097\/MD.0000000000015733","journal-title":"Medicine (Baltimore)"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa177","article-title":"Long-term consequences of acute kidney injury: a narrative review","volume":"14","author":"Gameiro J","year":"2021","unstructured":"Gameiro J, Marques F, Lopes JA. Long-term consequences of acute kidney injury: a narrative review. Clin Kidney J. 2021, 14:789-804. 10.1093\/ckj\/sfaa177","journal-title":"Clin Kidney J"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42922","article-title":"Catastrophic antiphospholipid syndrome: a complex diagnosis in the setting of lupus","volume":"15","author":"Liang J","year":"2023","unstructured":"Liang J, Mahmood R, Benchaala I, York R, Sarakbi H. Catastrophic antiphospholipid syndrome: a complex diagnosis in the setting of lupus. Cureus. 2023, 15:e42922. 10.7759\/cureus.42922","journal-title":"Cureus"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2022.09.002","article-title":"Emerging therapies in antiphospholipid syndrome","volume":"36","author":"Hubben A","year":"2022","unstructured":"Hubben A, McCrae KR. Emerging therapies in antiphospholipid syndrome. Transfus Med Rev. 2022, 36:195-203. 10.1016\/j.tmrv.2022.09.002","journal-title":"Transfus Med Rev"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000579","article-title":"Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus","volume":"8","author":"Bolla E","year":"2021","unstructured":"Bolla E, Tentolouris N, Sfikakis PP, Tektonidou MG. Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus. Lupus Sci Med. 2021, 8:000579. 10.1136\/lupus-2021-000579","journal-title":"Lupus Sci Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/283047-antiphospholipid-syndrome-and-catastrophic-antiphospholipid-syndrome-a-comprehensive-review-of-pathogenesis-clinical-features-and-management-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T03:45:51Z","timestamp":1723261551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/283047-antiphospholipid-syndrome-and-catastrophic-antiphospholipid-syndrome-a-comprehensive-review-of-pathogenesis-clinical-features-and-management-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.66555","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,10]]}}}